Assessing Lixte Biotechnology Holdings' Cash Burn and Financial Stability

Lixte Biotechnology Holdings' cash burn has decreased by 26% YoY, but it still lacks significant operating revenues. With a cash runway of 13 months, the company is at risk of running out of cash unless cash burn reduces drastically. The company's ability to raise more cash for growth through new shares or debt is uncertain.